NCT03456804View on ClinicalTrials.gov

ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

March 8, 2018

Primary Completion Date

March 15, 2023

Study Completion Date

May 9, 2023

Conditions
Castration Levels of TestosteroneCastration-Resistant Prostate CarcinomaMetastatic Prostate CarcinomaPSA ProgressionStage IV Prostate Adenocarcinoma AJCC v7
Interventions
DRUG

ESK981

Treatment with ESK981 for patients with metastatic castrate resistant prostate cancer

Trial Locations (2)

48201

Wayne State University/Karmanos Cancer Institute, Detroit

98109

Seattle Cancer Care Alliance, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Barbara Ann Karmanos Cancer Institute

OTHER

NCT03456804 - ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer | Biotech Hunter | Biotech Hunter